Clinical trial
Alemtuzumab to Treat Severe Aplastic Anemia
NCT00195624 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00195624 |
|---|---|
| Title | Alemtuzumab to Treat Severe Aplastic Anemia |
| Official title | A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Severe Aplastic Anemia, Refractory, Relapse |
| Intervention type | Biological, Drug |
| Interventions | Alemtuzumab (Campath ), Cyclosporine |
| Enrollment | 47 |
| Start date | Sep 15, 2005 |
| Primary completion | Apr 14, 2014 |
| Completion | Oct 15, 2018 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 7, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: